With respect to cell-of-origin, 47.8% (816/1708) of DLBCL patients had sufficient immunohistochemistry (CD10, BCL6 and IRF4/MUM1) to enable their tumour to be classified as either GCB or non-GCB; 47.6%, (761/1597) of those with no rheumatology episodes, and 49.5% (55/111) of those with three or more episodes. Here, BCL6 is linked to diffuse large B-cell lymphoma.